Closed Solicitation · DEPT OF DEFENSE
AI Summary
The Defense Health Agency intends to award a sole source contract for Illumina Urinary Pathogen Identification/Antimicrobial Resistance Enrichment Kits for Tripler Army Medical Center. Illumina, Inc. is the only vendor capable of providing the required kits for the Government-owned MiSeq Systems. Capability statements are due by April 22, 2026.
Notice of Intent to Sole Source HT941026N0046
THIS IS A NOTICE OF INTENT TO AWARD A SOLE SOURCE SUPPLY CONTRACT AND IS NOT A REQUEST FOR COMPETITIVE QUOTES.
The Defense Health Agency Contracting Activity (DHACA), Healthcare Contracting Division – West (HCD-W), intends to award a firm fixed price purchase order for Illumina Urinary Pathogen Identification (ID)/Antimicrobial Resistance (AMR) Enrichment Kits (UPIP) for the Department of Clinical Investigation (DCI), Tripler Army Medical Center, Hawaii, in accordance with the Federal Acquisition Regulation Revolutionary (FAR) Overhaul 12.102(a):
The North American Industry Classification System (NAICS) code for this requirement is 541714, Research and Technology in Biotechnology (except Nanobiotechnology); the business size standard is 1,000 (in employees). The Product Service Code (PSC) is 6550, Medical Equipment and Accessories and Supplies.
The objective of this sole source award is to procure one (1) Illumina Urinary Pathogen Identification (ID)/Antimicrobial Resistance (AMR) Enrichment Kit (UPIP) for Tripler Army Medical Center. Illumina, Inc., is the only vendor that makes sequencing supplies for the DCI Government-owned MiSeq Systems. These sequencing supplies are specific for the Government-owned MiSeq System. There is no reasonable expectation of receiving quotes from two or more small businesses. The proposed acquisition strategy is to justify as an Other Than Full and Open procurement on a sole source basis.
Illumina, Inc., is the only source that can meet the Government’s minimum requirements to provide the requested UPIP for DCI at Tripler Army Medical Center, HI.
This notice of intent is not a request for competitive proposals, and no solicitation document exists for this requirement. Sources interested in responding to this notice are required to submit a capability statement that includes management and technical data and cost information, in sufficient detail and with convincing evidence that clearly demonstrates the capability to provide the required equipment and preventive maintenance. Capability statements shall not exceed six (8.5 x 11 inch) pages using a font size no smaller than 10-point. All capability statements received by the due date of this notice will be considered by the Government. A request for documentation or additional information or submissions that only ask questions will not be considered as an affirmative response. A determination by the Government not to compete based on responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement or to proceed with a sole source purchase order.
If a vendor challenges the basis of this requirement, please email capability statements as a Microsoft Word or Adobe PDF attachment to Bobbie Dobberstein at bobbie.s.dobberstein.ctr@health.mil.
The closing date for challenges is no later than 1000 Pacific Daylight Time, Wednesday, April 22, 2026.
NO TELEPHONE REQUESTS/OFFERS WILL BE HONORED.
SOLE SOURCE ILLUMINA URINARY PATHOGEN IDENTIFICATION (ID)/ANTIMICROBIAL RESISTANCE (AMR) is a federal acquisition solicitation issued by DEPT OF DEFENSE. Review the full description, attachments, and submission requirements on SamSearch before the response deadline.
SamSearch Platform
AI-powered intelligence for the right opportunities, the right leads, and the right time.